Description: WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; and drug discovery services to pharmaceutical and biotech customers. In addition, the company offers consulting services for combinatorial chemistry and pharmaceuticals; and develops computer software and databases. Further, it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Home Page: www.wuxiapptec.com
288 Fute Zhong Road
Shanghai,
200131
China
Phone:
86 21 5046 1111
Officers
| Name | Title |
|---|---|
| Dr. Ge Li Ph.D. | Co-Founder, Chairman, President & CEO |
| Dr. Minzhang Chen Ph.D. | Co-CEO & Executive Director |
| Dr. Qing Yang Ph.D. | Co-CEO & Executive Director |
| Dr. Edward Hu M.B.A. | Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU |
| Ms. Ming Shi | Senior VP & CFO |
| Mr. Zhaohui Zhang | COO of China, Executive VP & Executive Director |
| Mr. Yuanzhou Zhang | Joint Company Secretary |
| Mr. Ruijia Tang | IR Director |
| Dr. Howard Wu J.D. | Senior VP, General Counsel & Global Head of Human Resources |
| Dr. Jingchao Dong Ph.D. | Senior VP & Head of RCS |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.6708 |
|---|---|
| Trailing PE: | 2.4364 |
| Price-to-Book MRQ: | 0.3507 |
| Price-to-Sales TTM: | 3.8085 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 41116 |